Core Viewpoint - The shareholders of Sai Sheng Pharmaceutical plan to reduce their holdings by up to 9.63 million shares, representing no more than 2% of the company's total share capital [1] Shareholder Information - Shareholder Ma Li holds 29.84 million shares, accounting for 6.2% of the total share capital [1] - Shareholder Liu Shuqin holds 8.748 million shares, accounting for 1.82% of the total share capital [1] - Both Ma Li and Liu Shuqin are acting in concert with the company's controlling shareholder, Ma Qiang [1]

Core Viewpoint - Sai Sheng Pharmaceutical (300485.SZ) announced that its shareholders, Ma Li and Liu Shuqin, plan to reduce their holdings in the company by up to 9,633,328 shares within a specified timeframe, representing a maximum of 2% of the total share capital [1] Shareholding Details - Ma Li holds 29,846,791 shares, accounting for 6.2% of the total share capital of 481,666,400 shares [1] - Liu Shuqin holds 8,748,000 shares, representing 1.82% of the total share capital [1] - Both Ma Li and Liu Shuqin are acting in concert with the company's controlling shareholder, Ma Qiao [1] Reduction Plan - The planned reduction of shares will occur within three months, starting from 15 trading days after the announcement date, specifically from October 21, 2025, to January 20, 2026 [1] - The reduction will be executed through centralized bidding and block trading methods [1]

Group 1 - The company Saisheng Pharmaceutical announced that two shareholders, Ma Li and Liu Shuqin, hold 29.8468 million shares and 8.748 million shares, representing 6.2% and 1.82% of the total shares respectively [1] - The shareholders plan to reduce their holdings by a total of no more than 9.6333 million shares, which is up to 2% of the total shares, between October 21, 2025, and January 20, 2026 [1] - The reduction will be executed through centralized bidding and block trading, with each method accounting for no more than 4.8167 million shares, or 1% of the total shares [1]

Group 1 - The core point of the news is that Beijing Saiseng Pharmaceutical Co., Ltd. announced a plan for share reduction by its major shareholders, which will not affect the company's control or governance structure [1][2] - Major shareholders Ma Li and Liu Shuqin plan to reduce their holdings by a total of up to 9.63 million shares, representing no more than 2% of the company's total share capital [1] - Ma Li currently holds 29.8468 million shares (6.2% of total shares), while Liu Shuqin holds 8.748 million shares (1.82% of total shares) [1] Group 2 - The reduction will occur between October 21, 2025, and January 20, 2026, through centralized bidding and block trading [1] - The reason for the reduction is personal funding needs, and the shares being sold were acquired prior to the company's initial public offering [1] - The reduction price will be determined based on market conditions at the time of sale, with a minimum price set at the initial public offering price [1]

Core Viewpoint - The company announced that its controlling shareholder and actual controller's concerted actors, Ma Li and Liu Shuqin, plan to reduce their holdings in the company by a total of no more than 9.633328 million shares, which accounts for up to 2% of the company's total share capital, due to personal funding needs [1] Summary by Relevant Sections - **Share Reduction Plan** - The planned share reduction will occur between October 21, 2025, and January 20, 2026 [1] - The reduction will be executed through centralized bidding and block trading methods [1] - **Reason for Reduction** - The primary reason for the share reduction is the personal funding needs of the shareholders [1] - **Compliance** - The share reduction plan complies with relevant laws and regulatory documents [1]

Core Viewpoint - The announcement from Sai Sheng Pharmaceutical indicates that major shareholders plan to reduce their holdings, which may impact the stock's performance and investor sentiment [1] Shareholder Information - Shareholder Ma Li holds 29.8468 million shares, representing 6.2% of the company [1] - Shareholder Liu Shuqin holds 8.748 million shares, representing 1.82% of the company [1] - Both shareholders are aligned with the company's controlling shareholder, Ma Biao [1] Reduction Plan - The shareholders plan to reduce their holdings by a total of up to 9.6333 million shares, which is not more than 2% of the total shares [1]

Core Viewpoint - The announcement from Sai Sheng Pharmaceutical indicates that two significant shareholders plan to reduce their holdings, which may impact the company's stock performance and investor sentiment [1] Group 1: Shareholder Actions - Ms. Ma Li holds approximately 29.85 million shares, accounting for 6.2% of the total share capital of about 482 million shares [1] - Ms. Liu Shuqin holds approximately 8.75 million shares, representing 1.82% of the total share capital [1] - Both shareholders plan to reduce their combined holdings by up to approximately 9.63 million shares, not exceeding 2% of the total share capital, within three months after the announcement [1] Group 2: Company Financials - For the year 2024, the revenue composition of Sai Sheng Pharmaceutical is projected to be 99.63% from the pharmaceutical manufacturing sector and 0.37% from other businesses [1] - As of the announcement, the market capitalization of Sai Sheng Pharmaceutical is 5.8 billion yuan [1]

赛升药业（300485）(300485.SZ)公告，公司股东马丽女士和刘淑芹女士计划在2025年10月21日至2026 年1月20日通过集中竞价和大宗交易方式减持公司股份数量合计不超过963.33万股，即不超过公司当前 总股本的2%。 ...

Group 1 - The core point of the article is that shareholders of Sai Sheng Pharmaceutical plan to reduce their holdings by a total of up to 9.633 million shares, which represents no more than 2% of the company's current total share capital [1] Group 2 - The reduction in shareholding will occur between October 21, 2025, and January 20, 2026, through centralized bidding and block trading methods [1]

证券代码：300485 证券简称：赛升药业 公告编号：2025-036 北京赛升药业股份有限公司 关于公司控股股东、实际控制人的一致行动人 减持股份的预披露公告 马丽女士和刘淑芹女士计划在自本公告披露之日起 15 个交易日后的 3 个月 内（即：2025 年 10 月 21 日至 2026 年 1 月 20 日），通过集中竞价和大宗交易 方式减持公司股份数量合计不超过 9,633,328 股，即不超过公司当前总股本 481,666,400 股的 2%。 近日，北京赛升药业股份有限公司（以下简称"公司"或"赛升药业"）收 到马丽女士、刘淑芹女士出具的《股份减持计划告知函》，现将有关情况公告如 下： 一、股东的基本情况 | 序号 | 股东名称 | 股东类型/职务 | 持有公司股份 的总数量（股） | 占公司总股 本的比例 | | --- | --- | --- | --- | --- | | 1 | 马丽 | 持股 5%以上股东、公司实际控制人的 一致行动人、董事、高级管理人员 | 29,846,791 | 6.2% | | 2 | 刘淑芹 | 公司实际控制人的一致行动人 | 8,748,000 | 1.82% ...